Kazuhiko Sugiyama

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 125 publications

Sex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis.

Sex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis.

Journal: ESMO gastrointestinal oncology

Published: August 28, 2026

Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy.

Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Expanding the potential of antibody-drug conjugates in gastrointestinal malignancies: beyond HER2 targets.

Expanding the potential of antibody-drug conjugates in gastrointestinal malignancies: beyond HER2 targets.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.

Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 08, 2025

Plain language summary about tirabrutinib in relapsed/refractory primary central nervous system lymphoma.

Plain language summary about tirabrutinib in relapsed/refractory primary central nervous system lymphoma.

Journal: Future oncology (London, England)

Published: October 31, 2025

Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.

Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.

Journal: Neuro-oncology

Published: July 17, 2025

Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?

Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?

Journal: ESMO open

Published: June 20, 2024

Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.

Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.

Journal: Neuro-oncology advances

Published: May 01, 2024

Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.

Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.

Journal: Neuro-oncology advances

Published: September 25, 2023

Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study.

Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study.

Journal: BMJ open

Published: April 24, 2023

Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors.

Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors.

Journal: Scientific reports

Published: April 02, 2023

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.

Journal: Internal medicine (Tokyo, Japan)

Published: March 01, 2023

Showing 1-12 of 125

Last Updated: 09/26/2026